UNSPSC 51292023: Escitalopram oxalate

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5U85DBW7LO, chemically known as 5-isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, (1s)- but more generally known as escitalopram oxalate, which bears US NIH Compound Identifier 146570.

UNSPSC 51292023 Escitalopram oxalate is a Commodity code that nominally describes a specific antidepressant pharmaceutical, but recent state and local solicitations tagged under this code show little alignment with escitalopram procurement itself. Instead, the code appears in opportunities spanning broader pharmaceutical supply and public health initiatives—naloxone procurement, generic multi-source drug distribution networks, and direct-to-manufacturer pharmacy programs. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work being bought reflects downstream pharmaceutical distribution and supply-chain management rather than a single active pharmaceutical ingredient.

Recent activity centers on three distinct procurement models. Seminole County, Florida issued an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP in January 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and awards effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 (HHS0017013) to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program. Activity spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing mechanisms pulling in broader multi-state participation. The code shows fragmented issuing-body activity with no repeat buyers across the three opportunities and no explicit set-aside designations identified in the available materials.